Polymolecular botanical drug of Orthosiphon stamineus extract (C5OSEW5050ESA) as a complementary therapy to overcome gemcitabine resistance in pancreatic cancer cells

10.1016/j.jtcme.2022.10.002

Ashwaq H.S. Yehya；Muhammad Asif；Amin M.S. Abdul Majid；Chern E. Oon

Journal of Traditional and Complementary Medicine

13卷1期（2023 / 01 / 01）

39 - 50

英文

Background and aim: Gemcitabine remains the cornerstone of pancreatic cancer treatment, despite exhibiting a modest effect on patient survival due to the development of drug resistance. Nuvastatic^(TM) polymolecular botanical drug Orthosiphon stamineus (O. stamineus) is a folklore Asian herbal medicine that is used for the treatment of a variety of ailments. However, little is known about the mechanism of actions of the Nuvastatic^(TM) polymolecular botanical drug of O. stamineus as a complementary therapy in resistant pancreatic cancer. It is postulated that the proprietary O. stamineus extract formulation (ID: C5EOSEW5050ESA) in Nuvastatic^(TM) may sensitise resistant pancreatic cancer cells to gemcitabine. This study was conducted to assess the cytotoxic activity and synergistic effects of C5EOSEW5050ESA in gemcitabine-resistant pancreatic cancer cells. Experimental procedure: The effects of C5EOSEW5050ESA treatment on cell viability, multidrug-resistant genes, epithelial-mesenchymal transition, cellular senescence, cell death, and Notch signalling pathway were evaluated in gemcitabine-resistant Panc-1 cells. Results and conclusion: C5EOSEW5050ESA sensitised gemcitabine resistant cells towards C5EOSEW5050ESA-gemcitabine combination treatment by reducing the expression of multidrug-resistant genes and epithelial-mesenchymal transition markers in gemcitabine-resistant cells compared to the control group, possibly through the inhibition of Notch signalling. This study provides valuable insight into using C5EOSEW5050ESA as a potential complementary treatment for resistant pancreatic cancer.

1. Al-Suede, F,Farsi, E,Ahamed, MKB,Ismail, Z,Majid, ASA,Majid, AMSA(2014).Marked antitumor activity of cat's whiskers tea (Orthosiphon stamineus) extract in orthotopic model of human colon tumor in nude mice.J Biochem Technol,3(5),170-176.
2. Al-Suede, FSR,Khadeer Ahamed, MB,Abdul Majid, AS(2014).Optimization of cat's whiskers tea (orthosiphon stamineus) using supercritical carbon dioxide and selective chemotherapeutic potential against prostate cancer cells.Evid Based Complement Altern Med,2014
3. Baron, JM,HoÈller, D,Schiffer, R(2001).Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes.J Invest Dermatol,116(4),541-548.
4. Brown, CM,Reisfeld, B,Mayeno, AN(2008).Cytochromes P450: a structure-based summary of biotransformations using representative substrates.Drug Metab Rev,40(1),1-100.
5. Çöl Arslan, S,Scheidereit, C(2011).The prevalence of TNFα-induced necrosis over apoptosis is determined by TAK1-RIP1 interplay.PLoS One,6(10),e26069.
6. Gao, J,Long, B,Wang, Z(2017).Role of Notch signaling pathway in pancreatic cancer.Am J Cancer Res,7(2),173.
7. Jiang, Z-S,Sun, Y-Z,Wang, S-M,Ruan, J-S(2017).Epithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression.J Cancer,8(12),2319.
8. Khamisipour, G,Jadidi-Niaragh, F,Jahromi, AS,Hojjat-Farsangi, M(2016).Mechanisms of tumor cell resistance to the current targeted-therapy agents.Tumor Biol,37(8),10021-10039.
9. Lieber, M,Mazzetta, J,Nelson-Rees, W,Kaplan, M,Todaro, G(1975).Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas.Int J Cancer,15(5),741-747.
10. Luk, SC-W,Siu, SW-F,Lai, C-K,Wu, Y-J,Pang, S-F(2005).Cell cycle arrest by a natural product via G2/M checkpoint.Int J Med Sci,2(2),64.
11. Luo, J,Tang, X,Dong, A(2014).Induction of cancer cell senescence: role of caffeic acid 3, 4-dihydroxy-phenethyl ester.Tumor Dormancy, Quiescence, and Senescence
12. Modrak, DE,Leon, E,Goldenberg, DM,Gold, DV(2009).Ceramide regulates gemcitabineinduced senescence and apoptosis in human pancreatic cancer cell lines.Mol Cancer Res,7(6),890-896.
13. Oon, CE,Strell, C,Yeong, KY,Ostman, A,Prakash, J(2015).SIRT1 inhibition in pancreatic € cancer models: contrasting effects in vitro and in vivo.Eur J Pharmacol,757,59-67.
14. Roche, J(2018).The Epithelial-To-Mesenchymal Transition in Cancer.Multidisciplinary Digital Publishing Institute.
15. Shafaei, A,Sultan Khan, M,Aisha, AF(2016).Flavonoids-rich Orthosiphon stamineus extract as new candidate for angiotensin I-converting enzyme inhibition: a molecular docking study.Mol,21(11),1500.
16. Sheena, E,Jothi, G(2015).Comparative phytochemical screening and antioxidant properties of in vitro and in vivo propagated Orthosiphon stamineus Benth (Lamiaceae).Asian J Pharmaceut Clin Res,8(4),216-220.
17. Song, HY,Wang, Y,Lan, H,Zhang, YX(2018).Expression of Notch receptors and their ligands in pancreatic ductal adenocarcinoma.Exp Ther Med,16(1),53-60.
18. Sung, H,Ferlay, J,Siegel, RL(2021).Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA A Cancer J Clin,71(3),209-249.
19. Tabana, YM,Al-Suede, FSR,Ahamed, MBK(2016).Cat's whiskers (Orthosiphon stamineus) tea modulates arthritis pathogenesis via the angiogenesis and inflammatory cascade.BMC Complement Altern Med,16(1),480.
20. Thompson, AA,Dilworth, S,Hay, RJ(1985).Isolation and culture of colonic epithelial cells in serum-free medium.Methods Cell Sci,9(2),117-122.
21. Tomono, T,Yano, K,Ogihara, T(2017).Snail-induced epithelial-to-mesenchymal transition enhances P-gp-Mediated multidrug resistance in HCC827 cells.J Pharmaceut Sci,106(9),2642-2649.
22. Uesaka, K,Boku, N,Fukutomi, A(2016).Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).Lancet,388(10041),248-257.
23. Vetrivel, P,Kim, SM,Saralamma, VVG(2019).Function of flavonoids on different types of programmed cell death and its mechanism: a review.J Biomed Res,33(6),363.
24. Wang, J,Seebacher, N,Shi, H,Kan, Q,Duan, Z(2017).Novel strategies to prevent the development of multidrug resistance (MDR) in cancer.Oncotarget,8(48),84559.
25. Wen, Z,Liao, Q,Hu, Y,You, L,Zhou, L,Zhao, Y(2013).A spheroid-based 3-D culture model for pancreatic cancer drug testing, using the acid phosphatase assay.Braz J Med Biol Res,46(7),634-642.
26. Wesolowska, O,Wisniewski, J,Bielawska-Pohl, A(2010).Stilbenes as multidrug resistance modulators and apoptosis inducers in human adenocarcinoma cells.Anticancer Res,30(11),4587-4593.
27. Yabuuchi, S,Pai, SG,Campbell, NR(2013).Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.Cancer Lett,335(1),41-51.
28. Yan, L,Liu, Y,Ma, X-F(2021).Triclabendazole induces pyroptosis by activating caspase-3 to cleave GSDME in breast cancer cells.Front Pharmacol,12
29. Yehya, A,Asif, M,Petersen, S(2018).Angiogenesis: managing the culprits behind tumorigenesis and metastasis.Med,54(1),8.
30. Yehya, AH,Al-Mansoup, MA,Al-Suede, FS(2022).Anti-tumor activity of NuvastaticTM (C5OSEW5050ESA) of orthosiphon stamineus and rosmarinic acid in an athymic nude mice model of breast cancer.Angiotherapy,6(2),612-619.
31. Yehya, AH,Asif, M,Kaur, G(2019).Toxicological studies of Orthosiphon stamineus (Misai Kucing) standardized ethanol extract in combination with gemcitabine in athymic nude mice model.J Adv Res,15,59-68.
32. Yehya, AH,Asif, M,Majid, AMA,Oon, CE(2020).Complementary effects of Orthosiphon stamineus standardized ethanolic extract and rosmarinic acid in combination with gemcitabine on pancreatic cancer.Biomed J,44(6),694-708.
33. Yehya, AH,Asif, M,Tan, YJ,Sasidharan, S,Majid, AMA,Oon, CE(2017).Broad spectrum targeting of tumor vasculature by medicinal plants: an updated review.J Herb Med,9,1-13.
34. Zhang, Z,Han, H,Rong, Y(2018).Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling.J Exp Clin Cancer Res,37(1),291.
35. Zhu, W,DePamphilis, ML(2009).Selective killing of cancer cells by suppression of geminin activity.Cancer Res,69(11),4870-4877.